Discordance Between Genetic Ancestry and Self-Reported Race Impacts Inference of Neuropsychiatric Burden in Alzheimer's Disease
Kumar, A.; Kannappan, B.; Ray, N. R.; Kurup, J. T.; Rosario, P. D.; De Vito, A. N.; Cuccaro, M. L.; Beecham, G. W.; Huey, E. D.; Reitz, C.
Show abstract
Introduction. Neuropsychiatric symptoms (NPS), including aggression, psychosis, anxiety, apathy, and depression, affect up to 85% of individuals with Alzheimer's disease (AD) and are among its most disabling and costly manifestations, accelerating cognitive and functional decline, institutionalization, mortality, and healthcare costs. NPS prevalence has largely been characterized using self-reported race. Whether NPS differs across genetically defined ancestry groups and whether self-reported race obscures these differences remains unknown, limiting accurate risk stratification and treatment development. Methods. Using whole-genome sequencing data from 7,118 ADSP participants, we defined three NPS clusters from the NPI-Q: early psychosis (CDR 0.5-1), late psychosis (CDR 2-3), and affective symptoms. Genetic ancestry was inferred by principal component clustering, identifying six groups (EUR, AFR, EAS, SAS, AMR, ADMIXED), and compared with self-reported race/ethnicity. NPS prevalence was compared across genetic ancestry groups and genetic ancestry and self-reported race using Fisher's exact and regression models. Results. Genetic ancestry assignment differed markedly from self-reported race, affecting NPS prevalence estimates. NPS prevalence also differed across ancestry groups; affective symptoms were highest in EAS (90%) and SAS (77%) and lowest in AFR (66%), while psychosis was highest in EAS (74%) and SAS (70%) and lowest in AMR (55%) and EUR (56%), with similar patterns for early and late psychosis. Discussion. Genetically defined ancestry alters NPS prevalence estimates in AD, suggesting that standard race categories obscure population-level disease burden and compromise risk stratification, screening, and trial design. Ancestry-associated differences suggest partially distinct genetic and environmental drivers, underscoring the need to incorporate genetic ancestry into AD research and care.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment 93%
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 93%
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 92%
Similar papers in this journal
- Frequency of Variants in Mendelian Alzheimer’s Disease Genes within the Alzheimer’s Disease Sequencing Project (ADSP) 95%
- Affective Neuropsychiatric Symptom Metrics in the National Alzheimers Coordinating Center Dataset 94%
- Olfactory impairment is related to tau pathology and neuroinflammation in Alzheimer's disease 93%
Similar papers in this journal
- African Ancestry GWAS of Dementia in a Large Military Cohort Identifies Significant Risk Loci 95%
- Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer’s disease 94%
- Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease 93%